Van ECK Associates Corp Acquires 3,982,439 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Van ECK Associates Corp boosted its stake in Bristol Myers Squibb by 67.8%, buying 3,982,439 shares to own 9,859,915 shares (about 0.48% of the company) worth roughly $444.7 million at quarter-end.
• Bristol Myers Squibb reported quarterly EPS of $1.26, missing estimates of $1.65 while revenue of $12.50 billion topped forecasts, and set FY2026 guidance of $6.05–$6.35 per share versus a sell‑side consensus of about $6.74.
• Recent clinical and regulatory wins — including an expanded FDA label for Sotyktu, positive Phase 3 mezigdomide results, and a late‑stage cancer trial meeting its primary endpoint — have driven investor interest, but analysts maintain a consensus Hold; the company also declared a $0.63 quarterly dividend (≈4.2% yield).

Van ECK Associates Corp boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 67.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,859,915 shares of the biopharmaceutical company's stock after buying an additional 3,982,439 shares during the quarter. Van ECK Associates Corp owned about 0.48% of Bristol Myers Squibb worth $444,682,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. Harbor Capital Advisors Inc. increased its holdings in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares during the period. Total Investment Management Inc. bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth about $40,000. Finally, Bank of Jackson Hole Trust increased its stake in Bristol Myers Squibb by 352.2% during the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 810 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $60.59 on Tuesday. The stock has a market capitalization of $123.38 billion, a P/E ratio of 17.56, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The firm has a 50 day moving average of $57.79 and a 200-day moving average of $51.12. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's payout ratio is currently 73.04%.

Analyst Ratings Changes

BMY has been the subject of a number of recent research reports. Guggenheim restated a "buy" rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an "overweight" rating and a $75.00 price target for the company. Cantor Fitzgerald reiterated a "neutral" rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Bank of America raised Bristol Myers Squibb from a "neutral" rating to a "buy" rating and increased their target price for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Finally, Leerink Partners raised their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 13th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $61.00.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA expanded Sotyktu’s label to include psoriatic arthritis after strong POETYK results — broadens commercial opportunity for the TYK2 franchise and supports near-term revenue upside. BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis
• Positive Sentiment: Positive Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed/refractory multiple myeloma — potentially a new commercial opportunity in hematologic oncology if regulatory filing follows. Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study
• Positive Sentiment: Company cancer treatment met its primary endpoint in a late-stage trial and showed survival benefits in a separate blood-cancer study — these clinical readouts reduce execution risk for oncology assets and support medium-term growth expectations. Bristol's cancer treatment meets main goal in late-stage trial
• Positive Sentiment: Coverage pieces and investor interest increased after the clinical/regulatory news, driving attention to BMY as a trending stock. Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
• Neutral Sentiment: Analysts maintain a consensus “Hold,” signaling mixed expectations despite the pipeline wins — could limit near-term re-rating until commercial data/filings confirm revenue impact. Bristol Myers Squibb Company Given Consensus Rating of "Hold" by Analysts
• Neutral Sentiment: Market/sector commentary (Zacks, Motley Fool) highlights pipeline momentum and legacy portfolio offsets — helpful context but not a direct catalyst. Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
• Neutral Sentiment: Macro/market reports (e.g., anticoagulants market outlook) underline long-term sector growth but are not company-specific catalysts. Anticoagulants Market Competitive Analysis Report 2025

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.